2021 Volume 38 Issue 3 Pages 143-147
The neurological disease was thought not to be able to get over even if the diagnosis is possible, however, treatment is enabled.
This report is made from the president view and describes it about as of a thing of the Japanese society of neurological therapeutics (JSNT) which I walked with members and the future prospects.
In other words, the neurotherapeutics guidelines that should be able to be called the axis on this society add it to result such as standard neurotherapeutics guideline publishing, in addition, globalization committee, an innovative drug development committee, regional clinician working group, the medical needs investigation working group might be well performed.
As the future prospects, we JSNT have to perform not only disease–modifying therapy but the complete drug for neurological disease based on big data and genetical analysis by AI with all member.
